Quinoxalin-2(1 h)-one derivatives as inhibitors against hepatitis C virus

Journal of Medicinal Chemistry

Volumn 54, Issue 16, 2011, Pages 5747-5768

  Liu, Rui ^a   Huang, Zhuhui ^c   Murray, Michael G ^c   Guo, Xiaoyong ^a   Liu, Gang ^a,b  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Tsinghua University   (China)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [CYCLOHEXYL(METHYL)AMINO] 3 (4 PHENYLTHIAZOL 2 YLAMINO) 7,8,9,10 TETRAHYDRO 5H PYRIDO[1,2 A]QUINOXALINE 6(6AH) ONE; 6 (DIETHYLAMINO) 7 (4 PHENYLTHIAZOL 2 YLAMINO)QUINOXALIN 2(1H) ONE; 6 [CYCLOHEXYL(METHYL)AMINO] 7 (4 PHENYLTHIAZOL 2 YLAMINO)QUINOXALIN 2(1H) ONE; 8 [CYCLOHEXYL(METHYL)AMINO] 7 (4 PHENYLTHIAZOL 2 YLAMINO)PYRROLO[1,2 A]QUINOXALIN 4(5H) ONE; ANTIVIRUS AGENT; N [7 [CYCLOHEXYL(METHYL)AMINO] 3 OXO 3,4 DIHYDROQUINOLIN 6 YLCARBAMOTHIOYL]BENZAMIDE; N [7 [CYCLOHEXYL(METHYL)AMINO] 3 OXO 3,4 DIHYDROQUINOXALIN 6 YLCARBAMOTHIOYL]FURAN 2 CARBOXAMIDE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; SYNTHESIS; TUMOR CELL LINE;

CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPACIVIRUS; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 80051887489     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200394x     Document Type: Article

References (28)

1. Tan, S. L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutic: current status and emerging strategies Nature Rev. Drug Discovery 2002, 1, 867-881 (Pubitemid 37361582)
2. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362 (Pubitemid 19117877)
3. Huang, Z. H.; Murray, M. G.; Secrist, J. A., III Recent development of therapeutics for chronic HCV infection Antiviral Res. 2006, 71, 351-362 (Pubitemid 44223780)
4. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way of forward in HCV treatment-finding the right path Nature Rev. Drug Discovery 2007, 6, 991-1000 (Pubitemid 350201789)
5. Hoognagle, J. H. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report N. Engl. J. Med. 1986, 315, 1575-1578
6. Smith, D. B.; Kalayanov, G.; Sund, C.; Winqvist, A.; Maltseva, T.; Leveque, V. J.-P.; Rajyaguru, S.; Pogam, S. L.; Najera, I.; Benkestock, K.; Zhou, X. X.; Kaiser, A. C.; Maag, H.; Cammack, N.; Martin, J. A.; Swallow, S.; Johansson, N. G.; Klumpp, K.; Smith, M. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4′-azidocytidine against hepatitis C virus replication: the discovery of 4′-azido-2′-deoxy- 2′-fluorocytidine and 4′-azido-2′-dideoxy-2′,2,- difluorocytidine J. Med. Chem. 2009, 52, 2971-2978
7. Wagner, R.; Larson, D. P.; Beno, D. W. A.; Bosse, T. D.; Darbyshire, J. F.; Gao, Y.; Gates, B. D.; He, W. P.; Henry, R. F.; Hernandez, L. E.; Hutchinson, D. K.; Jiang, W. W.; Kati, W. M.; Klein, L. L.; Koev, G.; Kohlbrenner, W.; Krueger, A. C.; Liu, J. R.; Liu, Y. Y.; Long, M. A.; Maring, C. J.; Masse, S. V.; Middleton, T.; Montgomery, D. A.; Pratt, J. K.; Stuart, P.; Molla, A.; Kempf, D. J. Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl- benzothia-diazines J. Med. Chem. 2009, 52, 1659-1669
8. Thompson, A. J. V.; McHutchison, J. G. Review article: investigational agents for chronic hepatitis C Aliment. Pharmacol. Ther. 2009, 29, 689-705
9. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y. P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y. Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protese Antimicrob. Agents Chemother. 2006, 50, 899-909 (Pubitemid 43327793)
10. Njoroge, F. G.; Chen, K. X.; Shih, N. Y.; Piwinski, J. J. Challenges in modern drug discovery: a case study of Boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection Acc. Chem. Res. 2008, 41, 50-59
11. Pierra, C.; Amador, A.; Benzaria, S.; Scott, E. C.; D'Amours, M.; Mao, J.; Mathieu, S.; Moussa, A.; Bridges, E. G.; Standring, D. N.; Sommadossi, J. P.; Storer, R.; Gosselin, G. Synthesis and pharmacokinetics of Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C- Methylcytidine J. Med. Chem. 2006, 49, 6614-6620 (Pubitemid 44657456)
12. Legrand-Abravanel, F.; Nicot, F.; Izopet, J. New NS5B polymerase inhibitors for hepatitis C Expert Opin. Invest. Drugs 2010, 19, 963-975
13. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.; Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.; Lewis, C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7- dimethyl-[1,2,4]triazolo[1,5- A ]pyrimidin-2-yl)methyl)-4-hydroxy-5,6- dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor J. Med. Chem. 2009, 52, 1255-1258
14. Lawitz, E.; Cooper, C.; Rodriguez-Torres, M.; Ghalib, R.; Lalonde, R.; Sheikh, A.; Bourgault, B.; Chauret, N.; Proulx, L.; McHutchison, J. Safety, tolerability and antiviral activity of VCH-916, a novel non-nucleoside HCV polymerase inhibitor patients with chronic HCV genotype-1 ingection J. Hepatol. 2009, 50, S37
15. Stauber, R. E.; Kessler, H. H. Drugs in development for hepatitis C Drugs 2008, 68, 1347-1359 (Pubitemid 351913433)
16. Lawrence, D. S.; Copper, J. E.; Smith, C. D. Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists J. Med. Chem. 2001, 44, 594-601 (Pubitemid 32162125)
17. Ajani, O. O.; Obafemi, C. A.; Nwinyi, O. C.; Akinpelu, D. A. Microwave assisted synthesis and antimicrobial activity of 2-quinoxalinone-3-hydrazone derivatives Bioorg. Med. Chem. 2010, 18, 214-221
18. Ries, U. J.; Priepke, H. W. M.; Hauel, N. H.; Handschuh, S.; Mihm, G.; Stassen, J. M.; Wienen, W.; Nar, H. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents Bioorg. Med. Chem. Lett. 2003, 13, 2297-2302 (Pubitemid 36724969)
19. NAr/coupling/demesylation reaction catalyzed by copper(I) as key step Adv. Synth. Catal. 2010, 352, 955-960
20. Zhang, L.; Liu, G.; Zhang, S. D.; Yang, H. Z.; Li, L.; Wu, X. H.; Yu, J. L.; Kou, B. B.; Xu, S.; Li, J.; Sun, G. C.; Ji, Y. F.; Cheng, G. F. Parallel approach for solution-phase synthesis of 2-quinoxalinol analogues and their inhibition of LPS-induced TNF-? release on mouse macrophages in vitro J. Comb. Chem. 2004, 6, 431-436 (Pubitemid 38698878)
21. Hu, L. Y.; Guo, J. Q.; Magar, S. S.; Fischer, J. B.; Burke-Howie, K. J.; Durant, G. J. Synthesis and pharmacological evaluation of N -(2,5-disubstituted phenyl)- N (3-substituted phenyl)- N methylguanidines as N -methyl- d -aspartate receptor ion-channel blockers J. Med. Chem. 1997, 40, 4281-4289 (Pubitemid 28042307)
22. Ferris, A. F.; Schutz, B. A. The preparation of carbodiimides, isocyanates, and isothiocyanates by metal ion-assisted elimination of mercaptan J. Org. Chem. 1963, 28, 71-74
23. Durust, Y.; Nohut, F. A new and convenient synthesis of some substituted thiohydantoins Synth. Commun. 1999, 29, 1997-2005 (Pubitemid 29193879)
24. Chicharro, R.; Castro, S. D.; Reino, J. L.; Arn, V. J. Synthesis of tri- and tetracyclic condensed quinoxalin-2-ones fused across the C-3-N-4 bond Eur. J. Org. Chem. 2003, 12, 2314-2326
25. Kim, H. J.; Sharon, A.; Bal, C.; Wang, J. N.; Allu, M.; Huang, Z. H.; Murray, M. G.; Bassit, L.; Schinazi, R. F.; Korba, B.; Chu, C. K. Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin a analogues in vitro J. Med. Chem. 2009, 52, 206-213
26. Frick, D. N.; Ginzburg, O.; Lam, A. M. A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities Methods Mol. Biol. 2010, 587, 223-233
27. Luo, G.; Hamatake, R. K.; Mathis, D. M.; Racela, J.; Rigat, K. L.; Lemm, J.; Colonno, R. J. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus J. Virol. 2000, 74, 851-863 (Pubitemid 30036222)
28. Pietschmann, T.; Lohmann, V.; Kaul, A.; Krieger, N.; Rinck, G.; Rutter, G.; Strand, D.; Bartenschlager, R. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture J. Virol. 2002, 76, 4008-4021 (Pubitemid 34250565)